| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
5-CFDA, Ingredients for the Working Solution 1. Add 10 mM 5-CFDA to DMSO to create a stock solution. Consider dissolving 1 milligram of 5-CFDA in 0.2172 mL of DMSO. It is suggested that the 5-CFDA storage solution be separated into smaller portions and kept at either -20°C or 2. One can prepare a 1-10 μM 5-CFDA working solution by loading the preset working solution into a storage solution that has been pre-prepared with either PBS or serum-free cell culture medium. Please make sure the 5-CFDA working solution is ready for usage by adjusting its concentration to suit the specific circumstances. Staining cells 1. Preparing the cell: Cells suspended: Using centrifugation, gather the cells, add PBS, and wash twice for five minutes each. Adherent cells: throw away the culture media, let the cells be broken down by trypsin, centrifuge, and then throw away the supernatant. Finally, add PBS and wash the cells twice, each for five minutes. 2. Work with 1 mL of the 5-CFDA working solution and centrifuge for 15 minutes. 3. Discard after 3–4 minutes at 4°C in a centrifuge at 400 g. 4. Wash the cells twice with PBS, giving them five minutes between washes. Using a flow cytometer or fluorescence microscope, resuspend the cells in 1 milliliter of serum-free or PBS and observe. Notifications 1. 5- It is advised to keep CFDA storage solution in the dark at -20°C or -80°C after aliquots and to steer clear of frequent freezing and thawing. It survives for one month at -20°C and six months at -80°C. 2. Could you please modify 5-CFDA to reflect the current situation? 3. The use of this product in clinical diagnosis or treatment, or in the production of food or medication, is strictly prohibited and should only be limited to scientific study conducted by qualified experts. Kindly put on a lab coat and disposable gloves for your own health and safety.
|
|---|---|
| References |
|
| Molecular Formula |
C25H16O9
|
|---|---|
| Molecular Weight |
460.39
|
| Exact Mass |
460.079
|
| CAS # |
79955-27-4
|
| Related CAS # |
6-CFDA;3348-03-6;5(6)-CFDA;124387-19-5
|
| PubChem CID |
133314
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
693.1±55.0 °C at 760 mmHg
|
| Flash Point |
241.9±25.0 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.702
|
| LogP |
2.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
34
|
| Complexity |
828
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
WPUZGNPQMIWOHE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H16O9/c1-12(26)31-15-4-7-19-21(10-15)33-22-11-16(32-13(2)27)5-8-20(22)25(19)18-6-3-14(23(28)29)9-17(18)24(30)34-25/h3-11H,1-2H3,(H,28,29)
|
| Chemical Name |
3',6'-Diacetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylic acid
|
| Synonyms |
5CFDA5-CFDA 5 CFDA CFDA 5 CFDA5CFDA-5
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~217.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1721 mL | 10.8604 mL | 21.7207 mL | |
| 5 mM | 0.4344 mL | 2.1721 mL | 4.3441 mL | |
| 10 mM | 0.2172 mL | 1.0860 mL | 2.1721 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03282266 | COMPLETED | Procedure: PADN Procedure: Sham operation |
Pulmonary Arterial Hypertension | Nanjing First Hospital, Nanjing Medical University | 2018-01-18 | Not Applicable |
| NCT02991872 | COMPLETED | Procedure: Blood draw | Virus Diseases | GlaxoSmithKline | 2016-12-16 | Phase 4 |
| NCT05104801 | UNKNOWN STATUS | Drug: sitravatinib Drug: tislelizumab |
Melanoma | Peking University Cancer Hospital & Institute | 2021-11 | Phase 2 |
| NCT05877001 | RECRUITING | Drug: Tislelizumab Drug: Regorafenib Other: HAIC |
Colorectal Liver Metastases | Peking University Cancer Hospital & Institute | 2023-05-30 | Phase 2 |
| NCT03156985 | COMPLETED | Type 2 Diabetes Mellitus | AstraZeneca | 2017-08-16 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
